Related Experiment Video

Updated: Jun 12, 2026

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
09:22

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Published on: February 28, 2021

Fine tuning chemotherapy to match BRCA1 status

Melissa Price1, Alvaro N A Monteiro

  • 1Risk Assessment, Detection, and Intervention Program, H. Lee Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA.

Biochemical Pharmacology
|June 1, 2010
PubMed

Insights

Targeted cancer therapies exploit oncogene addiction and DNA damage response disruptions. BRCA1 is a key biomarker for predicting patient response to Cisplatin, PARP, and microtubule inhibitors, advancing personalized cancer medicine.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Targeted cancer therapies often inhibit overactive oncogenes, exploiting tumor cell dependence known as oncogene addiction.
  • Loss-of-function mutations, particularly in DNA damage response pathways, create vulnerabilities that can be targeted therapeutically.

Purpose of the Study:

  • To review the role of BRCA1 as a predictive biomarker for targeted cancer therapies.
  • To explore the efficacy of Cisplatin, PARP inhibitors, and microtubule inhibitors in relation to BRCA1 status.
  • To discuss the advancement of personalized medicine through biomarker-guided treatment strategies.

Main Methods:

  • Literature review focusing on oncogene addiction and DNA damage response pathways.
  • Analysis of studies investigating BRCA1 as a response marker for specific chemotherapies and targeted agents.
  • Synthesis of current research on personalized medicine approaches in cancer treatment.

Main Results:

  • BRCA1 status is a significant predictor of response to DNA-damaging agents like Cisplatin.
  • PARP inhibitors demonstrate efficacy in tumors with BRCA1 mutations, leveraging synthetic lethality.
  • BRCA1 also serves as a marker for response to microtubule inhibitors, broadening therapeutic options.

Conclusions:

  • BRCA1 is a crucial biomarker for stratifying cancer patients for targeted therapies.
  • Combining insights from oncogene addiction and DNA repair pathways enhances therapeutic strategies.
  • Biomarker-driven approaches, like utilizing BRCA1, are essential for achieving personalized cancer medicine.

More Related Videos

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...